ClinicalTrials.gg
RecruitingNCT07319208COSMOS-TBIUpdated Nov 20, 2026

Efficacy of Early Continuous Infusion of HSS on the Neurological Outcome at 6 Months in TBI Patients.

A Phase 3 interventional study of Hypertonic saline solution in TBI Traumatic Brain Injury, sponsored by Nantes University Hospital. Recruiting at 25 sites in France. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Nantes University Hospital · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.
Updated Nov 20, 2026Site recruiting status changedEligibility revised+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
760
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 98 studies in Brain Injuries, Traumatic with a site in France — 23 open to participants now, 25 under way, 2 of them phase 3. Brain Injuries, Traumatic · France.

Planned enrollment
2nd of 66
760 · median 55
Started
2026
with 5 others
Phase 3
11 of 98
1 open now
Primary completion
2028-06
later than 18 of 24 live
Registered
95th of 98
by date
Lead sponsor
7 of 98
Nantes University Hospital

Among the 98 studies in Brain Injuries, Traumatic with a site in France, this one is the 2nd largest by planned enrollment of the 66 interventional ones that give a count, is one of 6 that started in 2026, is one of 11 in phase 3, reaches primary completion later than 18 of the 24 other live ones, and was the 95th registered.

Brain Injuries, Traumatic

1,725 studies on the registry are indexed under Brain Injuries, Traumatic; 450 are open to participants now.

Browse Brain Injuries, Traumatic studies →

Open to participants now

23 of the 98 studies in Brain Injuries, Traumatic with a site in France are open now. Recruiting first, the newest first:

17 more — sign in →

All 23 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 287 Brain Injuries, Traumatic studies recruiting now, 126 (44%) set no upper age limit and 119 (41%) stop at 75 or younger; 41 take children under 18; 53 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies in Brain Injuries, Traumatic with a site in France, or all of them as a file.
02

Study summary

The purpose of this study is to demonstrate the efficacy of early continuous intravenous infusion of hypertonic saline solution (HSS) to improve survival and independence in daily life activities (at 6 months) of patients with traumatic brain injury at high risk of intracranial hypertension.

03

Conditions studied

  • TBI Traumatic Brain Injury

Keywords

  • Traumatic brain injury
  • Saline Solution
  • Hypertonic
04

Who can participate

The criteria were revised on the registry on Nov 20, 2026. See what changed

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient admitted to intensive care unit
  • Traumatic brain injury with Glasgow Coma Scale ≤ 12
  • Intracranial pressure (ICP) monitoring based on the attending physician's clinical judgment, in accordance with guidelines or clinical/radiological signs considered at risk of intracranial hypertension
  • Inclusion during the first 12 hours after Intracranial pressure monitoring placement
  • Informed and signed consent
  • Health insurance

Exclusion criteria

Exclusion Criteria:

  • Glasgow Coma Scale (score = 3) and persistent abnormal pupillaryreactivity despite urgent therapy
  • Associated cervical spinal cord injury
  • Imminent death and do-not-resuscitate orders
  • Coma secondary to cardiac arrest
  • Pregnancy (serum or urine test performed in routine care)
  • Severe Cardiac insufficiency
  • Severe chronic renal insufficiency
  • Severe hepatic insufficiency: patient presenting with oedemato-ascitic decompensation of liver cirrhosis or patient with class C cirrhosis
  • High risk of follow-up difficulties after ICU discharge
  • Patients under court protection
  • Patient who does not speak French
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
760 participants (estimated)

Study arms

  • Experimental
    Hypertonic Saline Solution

    Continuous infusion of HSS (NaCl 20%) for 48 hours (can be prolonged during the period of intracranial hypertension)

    Drug: Hypertonic saline solution

  • No intervention
    Standard

    Standard of care

Interventions

  • DrugHypertonic saline solution

    Continuous infusion of HSS (NaCl 20%) for 48 hours (can be prolonged during the period of intracranial hypertension)

06

What researchers measure

Primary outcomes

  1. Efficacy of early continuous of HSS

    Survival : number of patients still alive

    Time frame: 3 months

  2. Efficacy of early continuous of HSS

    Rate of moderate to no dependency in activities in daily living at 6 months is defined as a Barthel Index of independence in activities in daily living ≥ 61.

    Time frame: 6 months

Secondary outcomes

  1. Treatment of intracranial hypertension

    Evolution of blood sodium level

    Time frame: 7 days

  2. Treatment of intracranial hypertension

    Evolution of blood chloride level

    Time frame: 7 days

  3. Treatment of intracranial hypertension

    Evolution of solute concentration in blood plasma

    Time frame: 7 days

  4. Neurological recovery

    Number of therapeutic interventions with the TIL (Therapeutic Intensity Level) scale.

    Time frame: 7 days

  5. Neurological recovery

    Survival : number of patients still alive

    Time frame: until 12 months

  6. Quality of life

    Score of EQ-5D-5L (5-level EuroQol-5D version) : minimum - maximal values: 1-5, higher scores mean a worse outcome.

    Time frame: until 12 month

  7. Quality of life

    Rates of patient living at home, at rehabilitation centers or at hospital

    Time frame: until 12 months

  8. Anterograde amnesia

    Galveston Orientation and Amnesia Test (G.O.A.T) : minimum - maximal values: 0-100, higher scores mean a better outcome.

    Time frame: until 6 months

  9. Neurocognitive functioning

    Montreal Cognitive Assessment (MOCA) : minimum - maximal values: 0-30, higher scores mean a better outcome.

    Time frame: 6 months

  10. Neurological outcome

    Glasgow Outcome Scale Extended (GOS-E) : minimum - maximal values: 1-8, higher scores mean a better outcome.

    Time frame: 6 months

  11. Tolerance

    Rates severe hypernatremia (Na\> 160 mmol/L)

    Time frame: 1 month

  12. Tolerance

    Rates of acute kidney injury

    Time frame: 1 month

  13. Tolerance

    Number of thrombotic events

    Time frame: 1 month

  14. Tolerance

    Number of central-pontine myelinolysis

    Time frame: 1 month

  15. Cost-effectiveness analysis

    Incremental cost-effectiveness ratio

    Time frame: 12 months

  16. Genetic biomarkers

    Single nucleotide polymorphism

    Time frame: 12 months

07

Study locations

23 of 25 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Jun 2028, 25 months after the start.

Of 30 phase 3 interventional studies under Brain Injuries, Traumatic, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 69. This study's planned 25 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2025
First posted
Jan 6, 2026
StartActual
Apr 21, 2026
Primary completionEst.
Jun 1, 2028
CompletionEst.
Jun 1, 2029
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added. 13 sites changed recruiting status (13 now recruiting)
Show 13 sites
  • CHU d'Angers · Angers, FranceNot yet recruiting→Recruiting
  • CH de Annecy Genevois · Épagny, FranceNot yet recruiting→Recruiting
  • CHU de Grenoble · Grenoble, FranceNot yet recruiting→Recruiting
  • HCL · Lyon, FranceNot yet recruiting→Recruiting
  • AP-HM · Marseille, FranceNot yet recruiting→Recruiting
  • CHU de Nancy · Nancy, FranceNot yet recruiting→Recruiting
  • CHU Lariboisière, AP-HP · Paris, FranceNot yet recruiting→Recruiting
  • GHU Paris Cité · Paris, FranceNot yet recruiting→Recruiting
  • CHU de Poitiers · Poitiers, FranceNot yet recruiting→Recruiting
  • CHU de Rouen · Rouen, FranceNot yet recruiting→Recruiting
  • CHU de St- Etienne · Saint-Etienne, FranceNot yet recruiting→Recruiting
  • CHU de Strasbourg · Strasbourg, FranceNot yet recruiting→Recruiting
  • CHRU de Tours · Tours, FranceNot yet recruiting→Recruiting
Show 2 added (2 France)
  • CHU d'Amiens · Amiens, France
  • CHU de Bordeaux · Bordeaux, France
Nov 20, 2026
Eligibility
1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedNational healthHealth insurance
Nov 20, 2026
Secondary outcomes
1 description edited
What changed in the outcomes
  • DescriptionTolerance#4: how it is measured was reworded
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    2 sites added. 13 sites changed recruiting status (13 now recruiting)
    Show 13 sites
    • CHU d'Angers · Angers, FranceNot yet recruiting→Recruiting
    • CH de Annecy Genevois · Épagny, FranceNot yet recruiting→Recruiting
    • CHU de Grenoble · Grenoble, FranceNot yet recruiting→Recruiting
    • HCL · Lyon, FranceNot yet recruiting→Recruiting
    • AP-HM · Marseille, FranceNot yet recruiting→Recruiting
    • CHU de Nancy · Nancy, FranceNot yet recruiting→Recruiting
    • CHU Lariboisière, AP-HP · Paris, FranceNot yet recruiting→Recruiting
    • GHU Paris Cité · Paris, FranceNot yet recruiting→Recruiting
    • CHU de Poitiers · Poitiers, FranceNot yet recruiting→Recruiting
    • CHU de Rouen · Rouen, FranceNot yet recruiting→Recruiting
    • CHU de St- Etienne · Saint-Etienne, FranceNot yet recruiting→Recruiting
    • CHU de Strasbourg · Strasbourg, FranceNot yet recruiting→Recruiting
    • CHRU de Tours · Tours, FranceNot yet recruiting→Recruiting
    Show 2 added (2 France)
    • CHU d'Amiens · Amiens, France
    • CHU de Bordeaux · Bordeaux, France
    Eligibility 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedNational healthHealth insurance
    Secondary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionTolerance#4: how it is measured was reworded
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07319208
Responsible party
Sponsor
First posted
Jan 6, 2026
Start date
Apr 21, 2026
Primary completion
Jun 1, 2028 (estimated)
Completion
Jun 1, 2029 (estimated)
Last update
Nov 20, 2026

Study contacts

Antoine ROQUILLY
Contact
antoine.roquilly@chu-nantes.fr
+33 2 53 48 22 30
Astrid GARREAU
Contact
astrid.garreau@chu-nantes.fr
+33 2 53 48 28 40

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion